z-logo
open-access-imgOpen Access
New Clues with Omalizumab for Broncho-Cutaneous Hyperresposiveness
Author(s) -
Erol Kilic
Publication year - 2016
Publication title -
the annals of clinical and analytical medicine
Language(s) - English
Resource type - Journals
ISSN - 2667-663X
DOI - 10.4328/jcam.3335
Subject(s) - medicine , omalizumab , dermatology , immunology , immunoglobulin e , antibody
 We retrospectively retrieved our records and identified Five patients who had used Omalizumab due to allergic asthma and co-existent physical urticaria. Patients received Omalizumab at a dose of 150 to 300 mg/month for 16 weeks. DLQI was measured before and after  three months of Omalizumab treatment. The beneficial effects of anti-IgE treatment observed in both allergic asthma and physical urticaria, as seen in our cases, suggests Ig E as a potential actor in the pathogenesis these disorders. 

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here